pharma QA – Page 24 – Pharma.Tips

Biosimilar regulatory deficiency during review during comparability protocol execution: bridging study planning and regulatory communication strategy

Biosimilar Regulatory Deficiency Investigation During Comparability Protocol Execution Within the complex landscape of pharmaceutical manufacturing, particularly in biosimilars, regulatory deficiencies can arise during the execution of comparability protocols. These deficiencies…

Half-life deviation during dispensing: patient safety assessment

Assessing Deviation in Half-life During Dispensing for Patient Safety In the realm of pharmaceutical manufacturing, particularly within the production of radiopharmaceuticals, deviations in the expected half-life during dispensing can pose…

Microbial limits failure during stability studies: GMP investigation and CAPA

Addressing Microbial Limits Failures during Stability Studies: A Comprehensive GMP Investigation In the world of pharmaceutical manufacturing, microbial contamination poses a significant risk, particularly during stability studies. When microbial limits…

Biosimilar method transfer failure across labs during CPV trending review: decision tree for lab method variability vs true product differences

Understanding Biosimilar Method Transfer Failures During CPV Trending Review In the rapidly evolving pharmaceutical landscape, the seamless transfer of biosimilar methods across laboratories is crucial for ensuring product consistency and…

Transport time excursion during dispensing: patient safety assessment

“`html Assessing Patient Safety Implications of Transport Time Variances During Dispensing In the pharmaceutical manufacturing realm, ensuring the integrity of products during and after dispensing is paramount, especially for radiopharmaceuticals,…

Labeling deviation during regulatory submission: regulatory communication strategy

Investigating Labeling Deviations During Regulatory Submission: A Comprehensive Communication Strategy Labeling deviations present significant challenges during regulatory submissions, particularly within the pharmaceutical sector where compliance dictates operational integrity. Pharmaceutical professionals…

Biosimilar comparability package deficiency after cell line or upstream change: FDA/EMA expectations for root cause, rework, and comparability justification

“`html Biosimilar Comparability Package Deficiency Investigation Following Cell Line or Upstream Changes Biosimilar developments are complex, and any deficiencies in comparability packages after cell line or upstream changes can pose…

Radiochemical purity OOS during inspection readiness: patient safety assessment

Investigation of Radiochemical Purity OOS During Readiness for Inspection: A Practical Framework Radiochemical purity failures can lead to significant challenges in pharmaceutical manufacturing, particularly in the production of radiopharmaceuticals. When…

Microbial limits failure during regulatory submission: regulatory communication strategy

Addressing Microbial Limits Failures in Regulatory Submission: A Structured Investigation Approach In the pharmaceutical manufacturing sector, particularly within veterinary medicines, regulatory submissions can face numerous challenges, especially regarding microbial limits.…

Biosimilar immunogenicity risk signal during stability pull comparisons: how to handle outliers and statistics without triggering inspection findings

Managing Immunogenicity Risk Signals in Biosimilar Stability Comparisons Pharmaceutical professionals often face challenges in handling unexpected immunogenicity signals arising from stability pull comparisons of biosimilars. When these signals appear, it…

Transport time excursion during transport to clinic: regulatory deviation handling

Handling Transport Time Excursions During Clinical Shipment: A Deviation Investigation Framework Transport time excursions during the shipment of radiopharmaceuticals to clinics can pose significant challenges in maintaining compliance with Good…

Residue limit non-compliance during stability studies: GMP investigation and CAPA

Investigating Residue Limit Non-Compliance During Stability Studies in Pharma Manufacturing In the highly regulated world of pharmaceutical manufacturing, ensuring compliance with residue limits during stability studies is critical. Non-compliance can…